BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Drug Discovery

InnoCare Prescribes Tafasitamab Combo for Diffuse Large B-Cell Lymphoma in Greater Bay Area's Early Access Program

The early access program of the Greater Bay Area allows designated medical institutions in the area to access drugs and medical devices that have been appr...

January 22, 2024 | News

Molecule AI Spearheads Pharmaceutical Transformation with AI-Driven Drug Discovery Innovations

Molecule AI, on a mission to accelerate drug discovery through the innovative use of artificial intelligence, is making significant...

January 20, 2024 | News

Eisai's Fycompa Injection Approved in Japan, Paving the Way for Non-Oral Antiepileptic Treatment

Fycompa is a first-in-class AED discovered at Eisai’s Tsukuba Research Laboratories. The agent is a highly selective, noncompetitive AMPA receptor an...

January 20, 2024 | News

Sanyou Introduces Super Trillion Peptide Molecule Discovery Platform

The Sanyou Super Trillion Peptide Molecule Discovery Platform is an integral part of the "Sanyou Super Trillion Innovative Biopharmaceutical Discovery Plat...

January 20, 2024 | News

Kindeva Drug Delivery Acquires Summit Biosciences, a Nasal Drug Development Specialist

The acquisition of Summit enhances Kindeva’s existing drug-delivery capabilities by adding a new drug-delivery platform, further expanding Kindeva&rs...

January 19, 2024 | News

Qure.ai and Project Data Sphere Merge Big Pharma Insights with Deep AI for Advancing Cancer Care

In a pivotal stride toward advancing cancer care, Qure.ai, a leader in artificial intelligence (AI) solutions for medical imaging, and Project Data Sp...

January 19, 2024 | News

Australia Achieves Positive Results in Phase Ib Study for Androgenic Alopecia Treatment

This study is led by Professor Rodney Sinclair and included 12 male and 4 female patients in Australia with androgenic alopecia (AGA). ...

January 15, 2024 | News

Japan Approves Neurolief's Relivion®, Paving the Way for At-Home Migraine Treatment.

Relivion® is a novel, non-invasive multi-channel brain neuromodulation technology. It stands out by concurrently stimulating the occipital and tri...

January 12, 2024 | News

SyntheticGestalt and Enamine Partner for AI-Driven Drug Discovery Model

SyntheticGestalt, a research and development company specializing in the application of AI to the life sciences domain, and Enamine, the world's leading pr...

January 11, 2024 | News

DNAnexus and Ovation Partner to Advance Drug Discovery with Precision Health Datasets

DNAnexus, Inc., the provider of the Precision Health Data Cloud, and Ovation, an omics data company committed to accelerating the development of preci...

January 11, 2024 | News

Debiopharm and ThinkingNodeLife.ai Partner for AI-Boosted Cancer Drug Development

Debiopharm, an independent biopharmaceutical company headquartered in Switzerland, and ThinkingNodeLife.ai (TNL), a trailblazer in AI Digital Cells Lab in ...

January 10, 2024 | News

OBI Pharma's partner Biosion announces FDA clearance for the Phase 1/2 study of OBI-992 (TROP2 ADC)

First clinical trial to evaluate the safety and efficacy of OBI-992 (a.k.a BSI-992), a novel antibody drug conjugate (ADC) targeting TROP2 - Dosing of f...

January 09, 2024 | News

Novartis Partners with Isomorphic Labs to Pioneer AI-Driven Drug Discovery

Fiona H. Marshall, President of Biomedical Research at Novartis, expressed her excitement, stating, "We are entering into this collaboration with Isomorphi...

January 08, 2024 | News

Akeso's Cadonilimab Granted NMPA Acceptance for First-Line Gastric Cancer Treatment.

This will be the second indication for which cadonilimab has received approval in China, following its use as a monotherapy treatment for recurrent or...

January 08, 2024 | News

Stay Connected